Feasibility of a Type 1 Diabetes Primary Prevention Trial Using 2000 IU Vitamin D3 in Infants From the General Population With Increased HLA-associated Risk

Ann N Y Acad Sci. 2006 Oct;1079:310-2. doi: 10.1196/annals.1375.047.

Abstract

Recent epidemiologic, immunologic, and NOD mouse studies suggest that intervention in the vitamin D system may be a successful method to prevent type 1 diabetes. Newborns at increased HLA-associated risk are randomized to receive either 400 or 2000 IU vitamin D3 by 1 month of age. We show that recruitment of babies from the general population for identification of HLA-associated risk status followed by enrollment to a randomized controlled prevention trial is feasible in Canada.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calcium / blood
  • Calcium / urine
  • Canada / epidemiology
  • Cholecalciferol / therapeutic use*
  • Diabetes Mellitus, Type 1 / epidemiology
  • Diabetes Mellitus, Type 1 / prevention & control*
  • Dose-Response Relationship, Drug
  • Feasibility Studies
  • Follow-Up Studies
  • HLA Antigens / genetics*
  • Humans
  • Infant, Newborn
  • Pilot Projects
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Substances

  • HLA Antigens
  • Cholecalciferol
  • Calcium